Table 1.
INDIVIDUAL SUBJECT DATA
| Cat # | Neomycin # days | Age at Initial Stimulation (weeks) | Age at Study (weeks) | # of Injections Left,Right | SG Density (% of normal) | CN: max X-Sect. Area (mm2) |
|---|---|---|---|---|---|---|
| NEONATALLY DEAFENED | ||||||
| K110 | 16 | -- | 14 | 2,2 | 42.5 | 4.94 |
| K112 | 16 | -- | 16 | 2,1 | 35.3 | 4.25 |
| CD384 | 30* | -- | 16.5 | 2,2 | 83.0 | 4.71 |
| CD387 | 30* | -- | 17 | 2,2 | 55.2 | 5.32 |
| CH537 | 20 | -- | 21.5 | 1,1 | NA | 4.78 |
| NEONATALLY DEAFENED, CONTRALATERAL TO COCHLEAR IMPLANT | ||||||
| K154 | 21 | 6 | 40 | --,1 | 40.1 | 5.29 |
| K158 | 19 | 7 | 41 | --,2 | 37.1 | 4.39 |
| K160 | 19 | 6 | 34 | --,2 | 37.3 | 4.05 |
| K163 | 19 | 6 | 20 | --,2 | 84.5 | 6.08 |
| K169 | 19 | 8 | 33 | --,2 | 23.7 | 4.89 |
| NORMAL ADULT CONTROLS | ||||||
| 423 | -- | -- | -- | 3,3 | -- | 6.62 |
| 596 | -- | -- | -- | 2,2 | -- | 7.06 |
| 654 | -- | -- | -- | 2,2 | -- | 7.21 |
| 944 | -- | -- | -- | 1,1 | -- | 6.42 |
*
2 subjects had measurable ABR thresholds after 24 days of 60 mg/kg/d neomycin, so the neomycin was increased to 70 mg/kg for the final 6 days after which both animals exhibited profound hearing loss.